All In Biotech

Drug Trial Radar · NCT01527305

A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia

An Open-Label, Prospective, Non-Comparative Study to Evaluate the Efficacy and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia

Last checked: Nov 20, 2026Latest source record: Oct 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

212

Actual

Start

Jun 22, 2012

Primary completion

Dec 31, 2013

Study completion Dec 31, 2013

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Feb 7, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness and safety of paliperidone palmitate in schizophrenic inpatients who have experienced recent exacerbation of acute schizophrenia (that is within past 4 weeks).

Conditions

  • Schizophrenia

Interventions

  • Paliperidone palmitateDrug

    Participants will receive 1 intramuscular (into muscle) injection of 150 milligram (mg) on Day 1 and 1 injection of 100 mg on Day 8. Participants will also receive the last 2 paliperidone intramuscular injections between 50 - 150 mg (based on effectiveness and safety profile), on Day 36 and Day 64.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total ScoreTime frame: Baseline (Week 0), Week 13

Locations

21 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Huzhou, China

  • Site not named

    Shanghai, China

  • Site not named

    Shantou, China

  • Site not named

    Suzhou, China

  • Site not named

    Wenzhou, China

  • Site not named

    Wuxi, China

  • Site not named

    Johor Bahru, Malaysia

  • Site not named

    Kuala Lumpur, Malaysia

  • Site not named

    Tanjong Rambutan, Malaysia

  • Site not named

    Busan, South Korea

  • Site not named

    Goyang, South Korea

  • Site not named

    Gyeonggi-do, South Korea

  • Site not named

    Jeonju, South Korea

  • Site not named

    Kyounggi, South Korea

  • Site not named

    Seoul, South Korea

  • Site not named

    Suwon, South Korea

  • Site not named

    Douliou City, Yunlin County, Taiwan

  • Site not named

    Kaohsiung City, Taiwan

  • Site not named

    New Taipei City, Taiwan

  • Site not named

    Taichung, Taiwan

  • Site not named

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.